Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vemurafenib

FDA-approved product (tablet, oral), marketed as Zelboraf.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vemurafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vemurafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vemurafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

    NCT01876641 · start 2013-10

    Registered record
    Registry ID
    NCT01876641
    Conditions
    Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma
    Interventions
    Vemurafenib + Cobimetinib, Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2013-10
    Completion
    2018-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma
    InterventionVemurafenib + Cobimetinib, Decitabine
    PhasePhase 1
    Registry statusTerminated

  • Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

    NCT01943422 · start 2013-10

    Registered record
    Registry ID
    NCT01943422
    Conditions
    Melanoma
    Interventions
    High-dose Interferon alfa-2b; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2016-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionHigh-dose Interferon alfa-2b; Vemurafenib
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

    NCT01849666 · start 2013-09

    Registered record
    Registry ID
    NCT01849666
    Conditions
    Malignant Melanoma, Neoplasms
    Interventions
    phenprocoumon; vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-04
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma, Neoplasms
    Interventionphenprocoumon; vemurafenib
    PhasePhase 1
    Registry statusCompleted

  • The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

    NCT01942993 · start 2013-09

    Registered record
    Registry ID
    NCT01942993
    Conditions
    Melanoma
    Interventions
    Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-09
    Completion
    2015-11
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionVemurafenib
    PhasePhase 2
    Registry statusTerminated

  • A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

    NCT01765569 · start 2013-07

    Registered record
    Registry ID
    NCT01765569
    Conditions
    Malignant Melanoma, Neoplasms
    Interventions
    Digoxin; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-06
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma, Neoplasms
    InterventionDigoxin; Vemurafenib
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

    NCT01897116 · start 2013-06

    Registered record
    Registry ID
    NCT01897116
    Conditions
    Melanoma
    Interventions
    Hydroxychloroquine (HCQ); Vemurafenib (VEM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-10-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionHydroxychloroquine (HCQ); Vemurafenib (VEM)
    PhasePhase 1
    Registry statusCompleted

  • Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

    NCT01781026 · start 2013-04

    Registered record
    Registry ID
    NCT01781026
    Conditions
    Melanoma
    Interventions
    Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-06
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionVemurafenib
    PhasePhase 2
    Registry statusCompleted

  • Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib

    NCT01983124 · start 2013-02

    Registered record
    Registry ID
    NCT01983124
    Conditions
    Malignant Melanoma Stage IV
    Interventions
    Fotemustine + Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2015-09
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma Stage IV
    InterventionFotemustine + Vemurafenib
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    NCT01771458 · start 2012-10

    Registered record
    Registry ID
    NCT01771458
    Conditions
    Reccurent/Metastatic Solid Tumor Disease
    Interventions
    Targeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus; Targeted therapy based on molecular profiling : Vemurafenib; Targeted therapy based on molecular profiling : Sorafenib; Targeted therapy based on molecular profiling : Erlotinib; Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Targeted therapy based on molecular profiling : Dasatinib; Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Targeted therapy based on molecular profiling : Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-12
    Enrolment
    742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReccurent/Metastatic Solid Tumor Disease
    InterventionTargeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus +7 more
    PhasePhase 2
    Registry statusCompleted

  • Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

    NCT01659151 · start 2012-08-03

    Registered record
    Registry ID
    NCT01659151
    Conditions
    Metastatic Melanoma
    Interventions
    High Dose Interleukin-2 (IL-2); ACT with TIL Infusion; Vemurafenib; Lymphodepletion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-03
    Completion
    2025-08-19
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma
    InterventionHigh Dose Interleukin-2 (IL-2); ACT with TIL Infusion; Vemurafenib; Lymphodepletion
    PhasePhase 2
    Registry statusCompleted

  • Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

    NCT01616199 · start 2012-08

    Registered record
    Registry ID
    NCT01616199
    Conditions
    Advanced BRAF-mutant Cancers
    Interventions
    PX-866; vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2012-08
    Completion
    2015-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced BRAF-mutant Cancers
    InterventionPX-866; vemurafenib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

    NCT01657591 · start 2012-07-27

    Registered record
    Registry ID
    NCT01657591
    Conditions
    Melanoma
    Interventions
    XL888; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07-27
    Completion
    2021-09-21
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionXL888; Vemurafenib
    PhasePhase 1
    Registry statusCompleted

  • Study of Vemurafenib, Carboplatin, and Paclitaxel

    NCT01636622 · start 2012-07-09

    Registered record
    Registry ID
    NCT01636622
    Conditions
    Advanced Cancers
    Interventions
    Vemurafenib; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07-09
    Completion
    2020-04-21
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers
    InterventionVemurafenib; Carboplatin; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

    NCT01611675 · start 2012-07

    Registered record
    Registry ID
    NCT01611675
    Conditions
    Melanoma
    Interventions
    Vemurafenib; Leflunomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-07
    Completion
    2014-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionVemurafenib; Leflunomide
    PhasePhase 1
    Registry statusTerminated

  • Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

    NCT01597908 · start 2012-06-04

    Registered record
    Registry ID
    NCT01597908
    Conditions
    Melanoma
    Interventions
    Dabrafenib; Vemurafenib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06-04
    Completion
    2019-04-25
    Enrolment
    704

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionDabrafenib; Vemurafenib; Trametinib
    PhasePhase 3
    Registry statusCompleted